Institution
Incyte
Company•Wilmington, Delaware, United States•
About: Incyte is a company organization based out in Wilmington, Delaware, United States. It is known for research contribution in the topics: Expression vector & Ruxolitinib. The organization has 1262 authors who have published 1875 publications receiving 75015 citations. The organization is also known as: Incyte Corporation & Incyte Inc..
Topics: Expression vector, Ruxolitinib, Cancer, Polynucleotide, Antibody
Papers published on a yearly basis
Papers
More filters
•
28 Oct 1994TL;DR: Chimeric proteins, also referred to as variants, and methods of producing, formulating and utilizing such proteins are disclosed in this paper, where five different general types of variants are disclosed.
Abstract: Chimeric proteins, also referred to herein as variants, and methods of producing, formulating and utilizing such proteins are disclosed. Five different general types of variants are disclosed.
51 citations
•
17 Dec 2010TL;DR: In this paper, the authors proposed fused derivatives of Formula I that modulate the activity of PI3Ks and are useful in the treatment of diseases related to the activity, including inflammatory disorders, immune-based disorders, cancer, and other diseases.
Abstract: The present invention provides fused derivatives of Formula I:
that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
51 citations
•
12 Oct 200151 citations
••
TL;DR: Interactions between the CXCR4 GPCR and the CxCL12 chemokine have been shown to mediate gene transcription and cellular proliferation in non‐transformed and transformed prostate epithelial cells, as well as motility/invasiveness in transformed cells.
Abstract: Introduction: The ectodomain shedding of epidermal growth factor receptor (EGFR) ligands, such as amphiregulin (AREG), by ADAMs (A Disintegrin And Metalloproteases) can be stimulated by G protein-coupled receptor (GPCR) agonists. Interactions between the CXCR4 GPCR and the CXCL12 chemokine have been shown to mediate gene transcription and cellular proliferation in nontransformed and transformed prostate epithelial cells, as well as motility ⁄ invasiveness in transformed cells. Objectives: In this report, we investigated the ability of CXCL12 to stimulate amphiregulin ectodomain shedding in non-transformed and transformed prostate epithelial cells that respond proliferatively to sub-nanomolar levels of CXCL12 and amphiregulin. Materials and Methods: Non-transformed N15C6 and transformed PC3 prostate epithelial cells were assessed for amphiregulin shedding, ADAM activation, Src phosphorylation and EGFR activation using ELISA, immunoblot, and immunoprecipitation techniques, and for proliferation using cell counting after stimulation with CXCL12 or vehicle. Results: The results of these studies identify CXCL12 as a novel inducer of amphiregulin ectodomain shedding and show that both basal and CXCL12-mediated amphiregulin shedding are ADAM10- and Src kinase-dependent in non-transformed N15C6 cells. In contrast, amphiregulin shedding is not amplified subsequent to stimulation with exogenous CXCL12, and is not reduced subsequent to metalloprotease- or Src kinase-inhibition, in highly aggressive PC3 prostate cancer cells. These data also show that CXCL12-mediated cellular proliferation requires EGFR transactivation in a Srcand ADAM-dependent manner in non-transformed prostate epithelial cells. However, these same mechanisms are dysfunctional in highly transformed prostate cancer cells, which secrete amphiregulin in an autocrine manner that cannot be repressed through metalloprotease- or Src kinase inhibition. Conclusion: These findings show that non-transformed and transformed prostate epithelial cells may employ different mechanisms to activate EGFR ligands and thereby utilize the EGFR axis to promote cellular proliferation.
51 citations
••
TL;DR: A potential new target for asthma therapy: A Disintegrin and Metalloprotease 10 (ADAM10) involvement in murine experimental asthma.
Abstract: Background: Elevated levels of CD23, a natural regulator of IgE production, have been shown to decrease the signs of lung inflammation in mice. The aim of this study was to study the involvement of ADAM10, the primary CD23 sheddase, in experimental asthma.
Methods: ADAM10 was blocked either by using mice with a B-cell-specific deletion of the protease or pharmacologically by intranasal administration of selective ADAM10 inhibitors. Airway hypersensitivity (AHR) and bronchoaveolar lavage fluid (BALF) eosinophilia and select BALF cytokine/chemokine levels were then determined.
Results: Using an IgE and mast cell–dependent mouse model, B-cell-specific ADAM10-/- mice (C57B/6 background) exhibited decreased eosinophilia and AHR when compared with littermate (LM) controls. Treatment of C57B/6 mice with selective inhibitors of ADAM10 resulted in an even further decrease in BALF eosinophilia, as compared with the ADAM10-/- animals. Even in the Th2 selective strain, Balb/c, BALF eosinophilia was reduced from 60% to 23% respectively. In contrast, when an IgE/mast cell–independent model of lung inflammation was used, the B-cell ADAM10-/- animals and ADAM10 inhibitor treated animals had lung inflammation levels that were similar to the controls.
Conclusions: These results thus show that ADAM10 is important in the progression of IgE-dependent lung inflammation. The use of the inhibitor further suggested that ADAM10 was important for maintaining Th2 levels in the lung. These results thus suggest that decreasing ADAM10 activity could be beneficial in controlling asthma and possibly other IgE-dependent diseases.
51 citations
Authors
Showing all 1267 results
Name | H-index | Papers | Citations |
---|---|---|---|
Patrick O. Brown | 183 | 755 | 200985 |
David Botstein | 165 | 468 | 212787 |
Inês Barroso | 113 | 301 | 76241 |
Alessandro M. Vannucchi | 94 | 715 | 35482 |
Ana M. Valdes | 84 | 334 | 26627 |
Mark C. Genovese | 79 | 364 | 26945 |
Michael B. Eisen | 71 | 170 | 89150 |
Jingyue Ju | 61 | 169 | 18952 |
Jeanne F. Loring | 60 | 177 | 14503 |
James Z. Wang | 57 | 225 | 21890 |
Emmett V. Schmidt | 50 | 150 | 9304 |
Günther Sperk | 50 | 124 | 10246 |
Robert C. Newton | 44 | 111 | 7369 |
Magnus Pfahl | 44 | 87 | 8064 |
William V. Williams | 44 | 168 | 7278 |